Latest Hodgkin's lymphoma Stories
- Published Final Guidance Recommending PIXUVRI as Cost Effective and Provides Patients with Aggressive B-cell Non-Hodgkin Lymphoma (NHL) Greater Access to Only Approved Therapy - SEATTLE,
Australian researchers say the combination of a psychiatry drug with a photosensitizer may work “synergistically” in patients with a certain kind of Non-Hodgkin’s Lymphoma. Raleigh,
Careful screening is recommended to protect Non-Hodgkin’s Lymphoma patients against this dangerous side effect of rituximab. Raleigh, NC (PRWEB) February 22,
Preclinical Study Results Published in the Journal Molecular Cancer Therapeutics Show Sustained Efficacy of EZH2 Inhibitor in Animal Models CAMBRIDGE, Mass., Feb.
A European study of compounds designed to stimulate stem cells finds that biologically similar versions work as well as the original. Raleigh, NC (PRWEB) February
HORSHAM, Pa., Feb. 12, 2014 /PRNewswire/ -- Janssen Biotech, Inc. ["Janssen"] today announced the U.S.
Immune cells undergo 'spontaneous' changes on a daily basis that could lead to cancers if not for the diligent surveillance of our immune system.
SAN DIEGO, Jan. 24, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc.
Grant Program Addresses Three Critical Areas of Blood Cancer Research WHITE PLAINS, N.Y., Jan.
- PIXUVRI Deemed Cost Effective for Patients with Multiply Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (NHL) - SEATTLE, Jan.
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.